On September 18, 2020, the company launched and operated a medical device for in vitro diagnostics - DIA®-SARS-CoV-2-Ag Enzyme-linked immunosorbent assay for the detection of coronavirus antigen SARS-CoV-2.
The test system is designed to detect SARS-CoV-2 coronavirus antigen in human serum and plasma samples by enzyme-linked immunosorbent assay using standard open-type ELISA equipment.
In coordination with the President of DiaPrep Systems Inc. of the USA, Favorov MO post-marketing research begins in 8 countries.
Comments